40% of Russian doctors do not accept “workplace snitching” in any case, according to a survey conducted by the RNC Pharma analyst company and the platform for doctors Medvestnik. Obviously, this answer had statistically significant differences between the two types of medical institutions—it was more often chosen by employees of private hospitals (48% against 34%).

In January–November 2021, the sales of veterinary drugs in the Russian retail market amounted to 19.9 billion rubles (retail prices, VAT included), up 4.7% from January–November 2020. The offline segment is under severe pressure from the rapidly developing online business, since the online sales increased 3.2 times in monetary terms (rubles). In physical terms, the growth rate was –6.6% in monetary dosage units (MDU), with the total sales volume of 155.7 million MDUs.

In January–November 2021, Russian manufacturers produced 546.4 billion rubles’ worth of pharmaceutical drugs (manufacturer’s prices, VAT included), up 20.1% from the same period in 2020. In physical terms, the production volume was 3.73 billion packages, down 16% from 2020. If calculated in minimum dosage units (MDU), the growth rate was also negative (–5.1%), with the production volume of 70.9 billion MDUs.

In January–November 2021, the retail sales of veterinary drugs through the top online marketplaces in Russia amounted to 673.3 million rubles (retail prices, VAT included), having increased 3.2 times from January–November 2020. The sales through marketplaces accounted for 3.5% of the total veterinary retail sales against 1.2% in January–November 2020. In physical terms, the sales declined 2.7 times from 2020, if calculated in minimum dosage units (MDU). The sales volume was 4.7 million MDUs.

In Q1–Q3 2021, the total volume of the online sales or reservations of pharmaceutical products (pharmaceutical drugs and parapharmaceuticals) in Russia amounted to RUB 141.6 billion (end-user prices, VAT included), 34.5% up from the same period in 2020. The total growth rate of the Russian pharmaceutical retail was just over 3%. After the disastrous results of Q1 2021, the largest growth was in Q2–Q3 2021.

This year’s growth rates of the Russian pharmaceutical retail market are in no way comparable to those in 2020. The panic and the associated rush demand have more or less subsided. With the inflation rates at a high level, the purchasing power leaves much to be desired, even despite the impressive income growth in Q2 and Q3. In addition, conventional pharmacies are under severe pressure from various online projects, which have been adding more and more services, including express delivery, which in some situations is critical for the consumer.

The Russian State Duma of the 8th convocation intends to continue working on the draft law that introduces restrictions for the pharmaceutical retail market and wholesale companies. At the same time, it is willing to revise certain provisions, including the maximum amount of marketing bonuses. While it may seem industry-specific, both the stability of the Russian pharmaceutical retail and the pricing policy at all stages of the movement of goods directly depend on that provision.

From January to October 2021, the sales of veterinary drugs in the Russian retail market amounted to RUB 18.5 billion (retail prices, VAT included), up 5% from January–October 2020. The most important factor for the growth rates was the inflation rate, as well as higher demand for premium segment products in certain regions. In minimum dosage units (MDU), the growth rate was –5.1%, with the sales volume of 144 million MDUs.

From January to October 2021, Russian manufacturers produced RUB 489.1 billion worth of pharmaceutical drugs (manufacturer’s prices, VAT included), down 21.2% from the same period in 2020. In physical terms, the growth rate was –16.8% due to the so-called “high base effect”, essentially meaning that large volumes of drugs used for the treatment of coronavirus were produced last year. The total production volume in January–October 2021 was 3.34 billion packages, or 61.1 billion minimum dosage units (MDU). Notably, the growth rate is higher if calculated in MDUs compared to packages, albeit still negative, –6.3%.

According to a survey conducted by the RNC Pharma analyst firm and the platform for doctors Medvestnik, 60.6% of Russian doctors believe that only trained physicians are qualified enough to be in charge of a healthcare facility.